From BZ Biotech Conference: PDS Biotechnology CEO Dr. Frank Bedu-Addo Says With Pending Results, Co. Believes PDS0203, Its Subunit Vaccine, Could Be Commercially Available in 2023; Says With Clinical Success, PDS0203 Could be competitive In Latin America